Literature DB >> 7657488

Multiple primary gastric and colorectal cancer in Japan.

Y Ikeda1, M Mori, K Kajiyama, Y Haraguchi, K Sugimachi.   

Abstract

The features of multiple primary gastric and colorectal cancer (MPGCC) were investigated, using 447 patients with primary gastric cancer and 199 with colorectal cancer during 1981-1992. Thirteen of these patients were found to have adenocarcinoma in both the stomach and colorectum. The increase rate for MPGCC and colorectal cancer was higher than that of primary gastric cancer (p < 0.05). Of the 13 patients with MPGCC, 8 showed synchronous MPGCC, while 5 showed metachronous MPGCC. Five of the 8 patients with synchronous MPGCC showed either Stage I or II in both lesions of the stomach and colorectum, and all 5 patients with metachronous MPGCC showed Stage I or II in the lesion of the second primary cancer. Since patients with MPGCC are expected to have a relatively good prognosis, both a preoperative examination and postoperative follow-up will be needed in order not to overlook lesions of the stomach or colorectum in patients with MPGCC.

Entities:  

Mesh:

Year:  1995        PMID: 7657488

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  3 in total

1.  Microsatellite instable double primary cancers of the colorectum and stomach exhibit less favorable outcome.

Authors:  Young-Ho Kim; Sang-Yong Song; Young-Dae Kwon; Dae-Shick Kim; Ho-Kyung Chun; Jong-Chul Rhee
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

2.  Prevalence of synchronous colorectal neoplasms detected by colonoscopy in patients with gastric cancer.

Authors:  Shin Saito; Yoshinori Hosoya; Kazutomo Togashi; Kentaro Kurashina; Hidenori Haruta; Masanobu Hyodo; Koji Koinuma; Hisanaga Horie; Yoshikazu Yasuda; Hideo Nagai
Journal:  Surg Today       Date:  2007-12-24       Impact factor: 2.549

3.  Multiple simultaneous gastric carcinomas.

Authors:  C Wittekind; M Klimpfinger; P Hermanek; A Tannapfel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.